IRTC
iRhythm Technologies, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
24.67
P/S
5.05
EV/EBITDA
-542.61
DCF Value
$111.33
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.6%
Operating Margin
-6.8%
Net Margin
-6.0%
ROE
-38.3%
ROA
-4.4%
ROIC
-5.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $208.9M | $5.6M | $0.17 |
| FY 2025 | $747.1M | $-44.6M | $-1.39 |
| Q3 2025 | $192.9M | $-5.2M | $-0.16 |
| Q2 2025 | $186.7M | $-14.2M | $-0.45 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.18
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.